EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial

S Ganame, T Walter, A Durand, A Lièvre, D Tougeron, J-Y Scoazec, E Baudin, C Lepage, O Boussari, J Hadoux

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115450 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von S Ganame und 9 weiteren Autor:innen. Beteiligte Einrichtung: FFCD Département Méthodologie & EPICAD U1231, INSERM, Dijon F-21079, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Neuroendocrine, Intestinal Neoplasms, Neuroendocrine Tumors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Institut National Du Cancer, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, NeuroendocrineIntestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedBevacizumabCamptothecinFluorouracilLeucovorinProof of Concept StudyProspective StudiesResearch DesignClinical Trials, Phase II as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

(hybrid) external control armFOLFIRIHistorical dataInverse probability weightingNeuroendocrine carcinomaPropensity scoreRandomization algorithm

Substanzen

BevacizumabCamptothecinFluorouracilLeucovorin

Autor:innen und Institutionen

  • FFCD Département Méthodologie & EPICAD U1231, INSERM, Dijon F-21079, France.
  • Service d'oncologie, ENETS Centre of Excellence, Hospices Civils de Lyon et Université de Lyon, Lyon F-69003, France.
  • Service d'Hépato-gastro-entérologie, CHU de Rennes, Rennes F-35033, France.
  • Service d'Hépato-gastro-Entérologie, CHU de Poitiers, Poitiers F-8600, France.
  • Service de Pathologie, Département de Biologie et Pathologie Médicale, Gustave Roussy, Villejuif F-94805, France; Université Paris Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Service d'Oncologie Endocrinienne, Département d'Imagerie, Gustave Roussy, Villejuif F-94805, France.

Förderung

  • Gilead Sciences
  • Institut National Du Cancer
  • European Regional Development Fund
  • Region Bourgogne-Franche-Comte
  • Agence nationale de la recherche

Zitieren

APA

Ganame, S., Walter, T., Durand, A., Lièvre, A., Tougeron, D., Scoazec, J. Y., Baudin, E., Lepage, C., Boussari, O., & Hadoux, J. (2025). Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115450

Vancouver

Ganame S, Walter T, Durand A, Lièvre A, Tougeron D, Scoazec JY, et al. Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115450

BibTeX
@article{Ganame2025,
  author = {Ganame, S and Walter, T and Durand, A and Lièvre, A and Tougeron, D and Scoazec, J-Y and Baudin, E and Lepage, C and Boussari, O and Hadoux, J},
  title = {Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115450}
}
Kostenlos starten →